Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
failed trials
Biotech
Nuvectis axes ovarian cancer program after seeing phase 1b data
Nuvectis Pharma dropped plans to develop NXP800 in ovarian cancer after tallying two unconfirmed partial responses in a phase 1b study.
Nick Paul Taylor
Jul 31, 2025 9:15am
Vyne's BET inhibitor fails phase 2 vitiligo trial, sinking stock
Jul 30, 2025 9:35am
GSK anti-TIM-3 antibody flunks ph. 3, as TIGIT fail costs $629M
Jul 30, 2025 5:27am
Atai's schizophrenia drug fails to improve cognition in phase 2
Jul 28, 2025 7:45am
Memo pushes kidney drug to phase 3 despite primary endpoint miss
Jul 25, 2025 5:30am
Roche's COPD drug flunks ph. 3, denting hopes of 2025 approval
Jul 21, 2025 4:38am
